Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
RESEARCH TOOLSreports
Neurosense Therapeutics Ltd. (NRSN) Stock Forecast & Price Target
86 Followers
See the Price Targets and Ratings of:
NRSN Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NRSN Stock 12 Month Forecast
Average Price Target
$3.00
▲(143.90% Upside)
| Highest Price Target$3.00 | Average Price Target$3.00 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Alliance Global Partners
$7.5
Buy
509.76%
Upside
Initiated
07/17/23
NeuroSense initiated with a Buy at Alliance Global PartnersNeuroSense initiated with a Buy at Alliance Global Partners
Best Analysts Covering Neurosense Therapeutics Ltd.
Which Analyst Should I Follow If I Want to Buy NRSN and Sell After:
1 Month
3 Months
1 Year
Success Rate
6/15 ratings generated profit
Average Return
-12.50%
reiterated a buy rating 5 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.50% per trade.
2 Years
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NRSN Analyst Recommendation Trends
Rating
Jul 23
Aug 23
Dec 23
May 24
Jul 24
Strong Buy
5
4
4
4
4
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
4
4
4
4
Each month's total comprises the sum of three months' worth of ratings.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
NRSN Financial Forecast
NRSN Stock Forecast FAQ
What is NRSN’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurosense Therapeutics Ltd.’s 12-month average price target is $3.00.
What is NRSN’s upside potential, based on the analysts’ average price target?
Neurosense Therapeutics Ltd. has 143.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NRSN a Buy, Sell or Hold?
Neurosense Therapeutics Ltd. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Neurosense Therapeutics Ltd.’s price target?
The average price target for Neurosense Therapeutics Ltd. is $3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 143.90% Increase from the current price of $1.23.
The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 143.90% Increase from the current price of $1.23.
What do analysts say about Neurosense Therapeutics Ltd.?
Neurosense Therapeutics Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of NRSN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.